21.67
price down icon2.69%   -0.60
after-market After Hours: 21.50 -0.17 -0.78%
loading
Genmab Adr stock is traded at $21.67, with a volume of 783.14K. It is down -2.69% in the last 24 hours and up +4.89% over the past month. Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.
See More
Previous Close:
$22.27
Open:
$21.92
24h Volume:
783.14K
Relative Volume:
0.58
Market Cap:
$13.90B
Revenue:
$2.62B
Net Income/Loss:
$966.70M
P/E Ratio:
14.44
EPS:
1.5004
Net Cash Flow:
$1.09B
1W Performance:
-8.29%
1M Performance:
+4.89%
6M Performance:
+10.17%
1Y Performance:
-23.40%
1-Day Range:
Value
$21.64
$22.09
1-Week Range:
Value
$21.64
$23.43
52-Week Range:
Value
$17.23
$28.54

Genmab Adr Stock (GMAB) Company Profile

Name
Name
Genmab Adr
Name
Phone
-
Name
Address
-
Name
Employee
2,638
Name
Twitter
@Genmab
Name
Next Earnings Date
2024-11-06
Name
Latest SEC Filings
Name
GMAB's Discussions on Twitter

Compare GMAB with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
GMAB
Genmab Adr
21.67 13.70B 2.62B 966.70M 1.09B 1.5004
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
456.87 120.48B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
545.46 59.88B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
392.24 44.31B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
670.33 36.65B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
301.13 32.46B 3.81B -644.79M -669.77M -6.24

Genmab Adr Stock (GMAB) Upgrades & Downgrades

Date Action Analyst Rating Change
Apr-01-25 Downgrade Bernstein Mkt Perform → Underperform
Mar-11-25 Upgrade William Blair Mkt Perform → Outperform
Feb-13-25 Upgrade Leerink Partners Market Perform → Outperform
Oct-08-24 Initiated Redburn Atlantic Buy
Sep-04-24 Resumed Morgan Stanley Equal-Weight
Aug-20-24 Downgrade JP Morgan Overweight → Neutral
Jul-15-24 Upgrade RBC Capital Mkts Sector Perform → Outperform
Feb-23-24 Upgrade BMO Capital Markets Market Perform → Outperform
Jan-22-24 Downgrade Citigroup Neutral → Sell
Dec-06-23 Upgrade UBS Neutral → Buy
Nov-10-23 Upgrade Deutsche Bank Hold → Buy
Nov-08-23 Upgrade DNB Markets Sell → Buy
Oct-18-23 Initiated Exane BNP Paribas Underperform
Sep-06-23 Downgrade RBC Capital Mkts Outperform → Sector Perform
Aug-24-23 Initiated BTIG Research Buy
Jul-14-23 Initiated HSBC Securities Buy
May-31-23 Initiated UBS Neutral
May-12-23 Initiated Morgan Stanley Underweight
Dec-20-22 Downgrade Citigroup Buy → Neutral
Nov-14-22 Initiated William Blair Mkt Perform
Nov-11-22 Downgrade Deutsche Bank Buy → Hold
Jun-24-22 Initiated BMO Capital Markets Market Perform
May-02-22 Initiated Cowen Market Perform
Mar-16-22 Upgrade UBS Neutral → Buy
Jan-31-22 Upgrade H.C. Wainwright Neutral → Buy
Jan-03-22 Downgrade Guggenheim Buy → Neutral
Dec-01-21 Initiated Berenberg Sell
Sep-16-21 Downgrade Jefferies Buy → Hold
Sep-07-21 Downgrade Morgan Stanley Equal-Weight → Underweight
Aug-24-21 Downgrade H.C. Wainwright Buy → Neutral
Apr-20-21 Initiated Deutsche Bank Buy
Jan-19-21 Downgrade Morgan Stanley Overweight → Equal-Weight
Sep-23-20 Downgrade Bryan Garnier Neutral → Sell
Sep-08-20 Initiated SVB Leerink Mkt Perform
Jun-25-20 Downgrade Credit Suisse Outperform → Neutral
Apr-23-20 Initiated Credit Suisse Outperform
Feb-24-20 Reiterated H.C. Wainwright Buy
Jan-13-20 Initiated SunTrust Buy
Dec-12-19 Downgrade Deutsche Bank Buy → Hold
Sep-13-19 Upgrade BofA/Merrill Neutral → Buy
Sep-12-19 Upgrade JP Morgan Neutral → Overweight
Aug-12-19 Initiated Guggenheim Buy
Aug-12-19 Initiated Morgan Stanley Overweight
Aug-12-19 Initiated RBC Capital Mkts Outperform
View All

Genmab Adr Stock (GMAB) Latest News

pulisher
Jul 24, 2025

Genmab A/S Sponsored ADR (NASDAQ:GMAB) Stake Lessened by Cerity Partners LLC - Defense World

Jul 24, 2025
pulisher
Jul 23, 2025

Genmab (GMAB) Upgraded to Strong Buy: Here's Why - MSN

Jul 23, 2025
pulisher
Jul 23, 2025

Genmab and BioNTech Launch Promising Study for Advanced Colorectal Cancer Treatment - TipRanks

Jul 23, 2025
pulisher
Jul 22, 2025

Wall Street Analysts See a 39.97% Upside in Genmab (GMAB): Can the Stock Really Move This High? - Zacks Investment Research

Jul 22, 2025
pulisher
Jul 19, 2025

Genmab A/S Sponsored ADR (NASDAQ:GMAB) Shares Purchased by Envestnet Asset Management Inc. - Defense World

Jul 19, 2025
pulisher
Jul 17, 2025

Genmab Bets On Antibody Innovations As Royalties Rule The Day - Finimize

Jul 17, 2025
pulisher
Jul 16, 2025

Genmab A/S FY2025 EPS Estimate Increased by William Blair - Defense World

Jul 16, 2025
pulisher
Jul 11, 2025

Genmab AS (ADR) (US3723032062.SG) latest stock news and headlines - yahoo.co

Jul 11, 2025
pulisher
Jul 11, 2025

Genmab A/S (NASDAQ:GMAB) Price Target Raised to $46.00 - Defense World

Jul 11, 2025
pulisher
Jul 10, 2025

Genmab and BioNTech’s Promising Cancer Trial: A Potential Game-Changer? - TipRanks

Jul 10, 2025
pulisher
Jul 10, 2025

Genmab and BioNTech’s GEN1042 Study: A New Hope for Cancer Treatment? - TipRanks

Jul 10, 2025
pulisher
Jul 08, 2025

Genmab and BioNTech’s Promising Immunoradiotherapy Study for Metastatic Tumors - TipRanks

Jul 08, 2025
pulisher
Jul 08, 2025

Genmab A/S Sponsored ADR (NASDAQ:GMAB) Receives Average Recommendation of “Moderate Buy” from Analysts - Defense World

Jul 08, 2025
pulisher
Jul 07, 2025

Genmab and BioNTech’s GEN1042 Study: A New Hope in Cancer Treatment - TipRanks

Jul 07, 2025
pulisher
Jul 06, 2025

Mirae Asset Global Investments Co. Ltd. Cuts Stock Position in Genmab A/S Sponsored ADR (NASDAQ:GMAB) - Defense World

Jul 06, 2025
pulisher
Jun 30, 2025

Envestnet Portfolio Solutions Inc. Sells 6,066 Shares of Genmab A/S Sponsored ADR (NASDAQ:GMAB) - Defense World

Jun 30, 2025
pulisher
Jun 19, 2025

GAMMA Investing LLC Boosts Holdings in Genmab A/S Sponsored ADR (NASDAQ:GMAB) - Defense World

Jun 19, 2025
pulisher
Jun 15, 2025

Genmab Announces Epcoritamab Investigational Combination Therapy Demonstrates High Response Rates in Patients with Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL) Eligible for Autologous Stem Cell Transplantation (ASCT) - GlobeNewswire Inc.

Jun 15, 2025
pulisher
Jun 02, 2025

Why Genmab Stock Smashed It On Monday - Barchart.com

Jun 02, 2025
pulisher
May 12, 2025

Weekly Stock Grader Analysis: Upgrades & Downgrades on Top Blue-Chip Stocks - InvestorPlace

May 12, 2025
pulisher
May 09, 2025

Applied Dna Sciences Inc (APDN)’s Day in Review: Closing at 0.85, Down by -2.41 - DWinneX

May 09, 2025
pulisher
May 09, 2025

Stock Surge: Genmab ADR (GMAB) Closes at 19.42, Marking a -5.73 Increase/Decrease - DWinneX

May 09, 2025
pulisher
May 09, 2025

Market Momentum Report: Evercore Inc (EVR)’s Positive Close at 216.74 - DWinneX

May 09, 2025
pulisher
Apr 23, 2025

Investing in Take-Two Interactive Software, Inc (TTWO) Is Getting More Attractive - knoxdaily.com

Apr 23, 2025
pulisher
Apr 23, 2025

Investing in Genmab ADR (GMAB): What You Must Know - knoxdaily.com

Apr 23, 2025
pulisher
Apr 23, 2025

Nucor Corp (NUE) may enjoy gains as insiders got busy in the recent days - knoxdaily.com

Apr 23, 2025
pulisher
Apr 17, 2025

EWTX Stock Sees Surge of Approximately 4.24% in Last Five Days - knoxdaily.com

Apr 17, 2025
pulisher
Apr 16, 2025

GMAB or RGEN: Which Is the Better Value Stock Right Now? - Yahoo Finance

Apr 16, 2025
pulisher
Apr 16, 2025

Should Value Investors Buy Genmab (GMAB) Stock? - Yahoo Finance

Apr 16, 2025
pulisher
Apr 15, 2025

Genmab ADR (NASDAQ: GMAB) Jumps 1.19% In Recent Session. Here’s Everything You Need To Know. - Stocksregister

Apr 15, 2025
pulisher
Apr 10, 2025

AGCO Corp (AGCO) Beta Value: Understanding the Market Risk - News Heater

Apr 10, 2025
pulisher
Apr 04, 2025

Evercore Inc’s Mixed Bag: Down -29.24% in 6 Months, Down -20.22% in 30 Days - investchronicle.com

Apr 04, 2025
pulisher
Apr 04, 2025

GMAB’s Debt-to-Equity Ratio at 0.03: What It Means for Genmab ADR’s Future - investchronicle.com

Apr 04, 2025
pulisher
Apr 03, 2025

CZR Stock Sees Decline of Approximately -4.82% in Last Five Days - knoxdaily.com

Apr 03, 2025
pulisher
Apr 01, 2025

Genmab gets European approval for cervical cancer treatment - medwatch.com

Apr 01, 2025
pulisher
Mar 31, 2025

Magnite Inc (MGNI) may enjoy gains as insiders got busy in the recent days - knoxdaily.com

Mar 31, 2025
pulisher
Mar 26, 2025

DLocal Limited (DLO) Shares Decline Despite Market Challenges - The News Heater

Mar 26, 2025
pulisher
Mar 12, 2025

Genmab ADR Inc. (GMAB) Price Performance: The Role of Supply and Demand - The InvestChronicle

Mar 12, 2025
pulisher
Feb 07, 2025

Views of Wall Street’s Leading Experts on Genmab ADR - SETE News

Feb 07, 2025
pulisher
Feb 07, 2025

What is Core & Main Inc (CNM) Stock Return on Shareholders’ Capital? - SETE News

Feb 07, 2025
pulisher
Feb 07, 2025

There is no doubt that Kite Realty Group Trust (KRG) ticks all the boxes. - SETE News

Feb 07, 2025
pulisher
Jan 17, 2025

GMAB vs. QGEN: Which Stock Is the Better Value Option? - MSN

Jan 17, 2025
pulisher
Jan 14, 2025

Genmab (GMAB) Upgraded to Buy: Here's What You Should Know - Yahoo Finance

Jan 14, 2025
pulisher
Jan 08, 2025

Genmab stock holds Buy rating on positive trial results - Investing.com

Jan 08, 2025
pulisher
Nov 18, 2024

10 Biggest Biotechnology Companies - Investopedia

Nov 18, 2024
pulisher
Nov 11, 2024

Weekly Upgrades and Downgrades - InvestorPlace

Nov 11, 2024

Genmab Adr Stock (GMAB) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$74.89
price down icon 3.43%
$36.80
price down icon 0.86%
$107.28
price up icon 2.00%
$26.37
price down icon 1.09%
$107.50
price down icon 2.32%
biotechnology ONC
$301.13
price up icon 0.40%
Cap:     |  Volume (24h):